{"id":49194,"date":"2022-10-05T16:01:54","date_gmt":"2022-10-05T14:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/"},"modified":"2022-10-05T16:01:54","modified_gmt":"2022-10-05T14:01:54","slug":"synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/","title":{"rendered":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx<\/a> (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), announces support for the nations\u2019 payers in their coverage and prescribing determinations for the AD drug, lecanemab<\/a> when it is approved as expected by the FDA. Evidence of the drug\u2019s efficacy with safety observations are left to the FDA, but payers, healthcare providers and patients need a definitive diagnosis to ensure appropriate prescribing.\n<\/p>\n

<\/a><\/p>\n

\n\u201cSDx is encouraged by this much needed, breakthrough treatment but payers will likely require an accurate diagnosis to finalize prescribing guidelines to ensure access for the most appropriate patients and address issues associated with prior authorizations and copays,\u201d says Frank Amato, CEO and president, SDx. \u201cPayers can look to the DISCERN<\/a>TM<\/sup> test to support these determinations and confirm an accurate diagnosis of AD for patients in early dementia.”\n<\/p>\n

\nDISCERN<\/a> is a CLIA certified, minimally invasive skin test that <\/b>assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation\u2014hallmarks of AD at autopsy. SDx developed DISCERN<\/a> to provide healthcare professionals a test to identify and distinguish AD in people recently diagnosed with dementia, even in the presence of co-morbid pathologies. DISCERN has been autopsy validated to identify AD against the NIH gold standard<\/a> of dementia in life and plaque and tau at death.\n<\/p>\n

\n\u201cWith the anticipated approval of this new drug, education is necessary to provide payers and healthcare providers with the most accurate diagnosis and to ensure treatment is optimized for appropriate patients,\u201d Amato continues. \u201cBy utilizing the DISCERN test, all stakeholders can avoid unnecessary, invasive and expensive diagnostic procedures conventionally used to diagnose AD in people with dementia.\u201d\n<\/p>\n

\nDISCERN, which has demonstrated 95% sensitivity and 95% specificity in the diagnosis and management of AD, improves access to care and patient satisfaction. The test is the first of its kind to earn Proprietary Laboratory Analyses (PLA) Codes 206U and 207U.\n<\/p>\n

\nAbout SYNAPS Dx<\/b>\n<\/p>\n

\nSYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD). The Company offers DISCERN\u2122, the first highly accurate, minimally invasive test supporting a clinician\u2019s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx\u2019s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https:\/\/discerntest.com\/<\/a>. For more information on the Company, visit https:\/\/www.synapsdx.com\/<\/a>. Contact: info@synapsdx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Caroline Chambers
\n
CPR Communications
\n
cchambers@cpronline.com<\/a>
201.641.1911 x 21\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), announces support for the nations\u2019 payers in their coverage and prescribing determinations for the AD drug, lecanemab when it is approved as expected by the FDA. Evidence of the drug\u2019s efficacy … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49194","6":"format-standard","7":"category-industry"},"yoast_head":"\nSYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), announces support for the nations\u2019 payers in their coverage and prescribing determinations for the AD drug, lecanemab when it is approved as expected by the FDA. Evidence of the drug\u2019s efficacy ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T14:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease\",\"datePublished\":\"2022-10-05T14:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/\"},\"wordCount\":483,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005505\\\/en\\\/1592693\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/\",\"name\":\"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005505\\\/en\\\/1592693\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"datePublished\":\"2022-10-05T14:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005505\\\/en\\\/1592693\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005505\\\/en\\\/1592693\\\/21\\\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), announces support for the nations\u2019 payers in their coverage and prescribing determinations for the AD drug, lecanemab when it is approved as expected by the FDA. Evidence of the drug\u2019s efficacy ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T14:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease","datePublished":"2022-10-05T14:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/"},"wordCount":483,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/","url":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/","name":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","datePublished":"2022-10-05T14:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221005005505\/en\/1592693\/21\/SYNAPS_DX_LOGO_COLOR_HORIZONTAL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synaps-dxs-discern-diagnostic-test-supports-payer-coverage-and-prescribing-decisions-for-lecanemab-expected-breakthrough-treatment-of-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SYNAPS Dx\u2019s DISCERN\u2122 Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49194"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49194\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}